

1 **Full Title: Bayesian hierarchical modeling of joint**  
2 **spatiotemporal risk patterns for Human Immunodeficiency**  
3 **Virus (HIV) and Tuberculosis (TB) in Kenya**  
4 **Short Title: Spatiotemporal modeling of joint risk patterns**  
5 **of HIV and TB in Kenya**

6 Verrah A. Otiende<sup>1\*</sup>, Thomas N. Achia<sup>2</sup>, Henry G. Mwambi<sup>2</sup>

7 <sup>1</sup>Department of Mathematical Sciences, Pan African University Institute of Basic Sciences  
8 Technology and Innovation, Nairobi, Kenya

9 <sup>2</sup>School of Mathematics, Statistics & Computer Science, University of KwaZulu Natal,  
10 Pietermaritzburg, South Africa

11 \*Corresponding author

12 Email: [otiende.verrah@students.jkuat.ac.ke](mailto:otiende.verrah@students.jkuat.ac.ke); [verrahodhiambo@gmail.com](mailto:verrahodhiambo@gmail.com)

13 VO, TO and HM conceived and designed the study. VO wrote the first draft of the manuscript.  
14 VO and TO analyzed data. HM contributed to data analysis. All authors contributed to reviewing  
15 literature, interpretation of the results and writing of the manuscript. All authors read and  
16 approved the final manuscript.

## 17 **Abstract**

18 The spatiotemporal modeling of multiple diseases simultaneously is a recent extension that  
19 advances the space-time analysis to model multiple related diseases simultaneously. This  
20 approach strengthens inferences by borrowing information between related diseases. Numerous  
21 research contributions to spatiotemporal modeling approaches exhibit their strengths differently  
22 with increasing complexity. However, contributions that combine spatiotemporal approaches to  
23 modeling of multiple diseases simultaneously are not so common. We present a full Bayesian  
24 hierarchical spatio-temporal approach to the joint modeling of Human Immunodeficiency Virus  
25 and Tuberculosis incidences in Kenya. Using case notification data for the period 2012 - 2017,  
26 we estimated the model parameters and determined the joint spatial patterns and temporal  
27 variations. Our model included specific and shared spatial and temporal effects. The specific  
28 random effects allowed for departures from the shared patterns for the different diseases. The  
29 space-time interaction term characterized the underlying spatial patterns with every temporal  
30 fluctuation. We assumed the shared random effects to be the structured effects and the disease-  
31 specific random effects to be unstructured effects. We detected the spatial congruence in the  
32 distribution of Tuberculosis and Human Immunodeficiency Virus in approximately 29 counties  
33 around the western, central and southern regions of Kenya. The distribution of the shared relative  
34 risks had minimal difference with the Human Immunodeficiency Virus disease-specific relative  
35 risk whereas that of Tuberculosis presented many more counties as high-risk areas. The  
36 flexibility and informative outputs of Bayesian Hierarchical Models enabled us to identify the  
37 similarities and differences in the distribution of the relative risks associated with each disease.  
38 Estimating the Human Immunodeficiency Virus and Tuberculosis shared relative risks provide  
39 additional insights towards collaborative monitoring of the diseases and control efforts.

## 40 **Introduction**

41 Disease mapping as a modeling approach is commonly used to describe the geographical  
42 distribution of disease burden thereby generating hypotheses on their possible causes and  
43 differences [1]. Statistical methods for characterization of the geographical variations have  
44 contributed significantly towards advancing the focus of disease mapping to incorporate other  
45 analysis techniques. Including the time dimension has given rise to the spatiotemporal modeling  
46 of the variation of disease risk which enables simultaneously studying the spatial patterns and  
47 temporal variations thereby giving deeper insights over purely spatial mapping [2,3]. Another  
48 extension is the joint spatial modeling of multiple related diseases with common risk factors,  
49 which outspread the standard univariate disease mapping methodologies. It generates both the  
50 shared and divergent trends thereby increasing the estimation precision of disease risk [4]. The  
51 latest and most recent extension is the joint spatiotemporal modeling of multiple diseases. This  
52 approach advances the space-time analysis to model multiple diseases simultaneously thereby  
53 strengthening inference by borrowing information across neighboring regions and between  
54 related diseases or sub-populations with common aetiological factors [5]. The benefits of  
55 borrowing information lie in the ability to observe concurrency of patterns and to allow  
56 conditioning of one disease on others [6] which is very valuable when accounting for uncertainty  
57 due to sparse disease count or underreporting [7]

58 Studies combining spatiotemporal approaches to modeling multiple diseases simultaneously are  
59 not so common despite the development and application of novel computational techniques.  
60 Reviews from literature show few contributions of these approaches that exhibit their strengths  
61 differently with increasing complexities. [8] used a Bayesian factor analysis approach to

62 combine the space-time disease mapping and joint modeling of different cancers. [9] used a full  
63 Bayesian hierarchical model to split the disease risks into shared and disease-specific  
64 spatiotemporal components. Their definition of multiple diseases was male and female  
65 subpopulations. [10] also applied a full Bayesian hierarchical approach to their spatiotemporal  
66 model to estimate the relative risk of various cancers while adjusting for age and gender. Using  
67 the hierarchical Bayesian factor models, [11] combined the dynamic factor analytic models with  
68 space-time disease mapping and produced a flexible framework for jointly analyzing multiple  
69 related diseases. Another study by [12] compared three formulations of the spatiotemporal  
70 shared component model on five diseases and examined the changes in the shared factors over  
71 time.

72 Incorporating the spatiotemporal modeling approaches to modeling of multiple diseases  
73 simultaneously adds significant complexity to the model structure [13]. The Bayesian  
74 hierarchical modeling approach makes an appropriate framework for solving complexities in the  
75 spatiotemporal structures [9,10,14,15]. The uniqueness of the Bayesian approach that  
76 differentiates it from other classical approaches is its robustness to interpretation of the posterior  
77 estimates and generating inferences of all model parameters [16].

78 The feasibility of using case notifications as a surrogate of population-based studies to estimate  
79 the shared and disease-specific risks of multiple diseases is also unknown. Against this  
80 background, we investigate the spatial and temporal patterns of Human Immunodeficiency Virus  
81 (HIV) and Tuberculosis (TB) burden in Kenya jointly using case notification data for a six-year  
82 period and characterize the areas with unusually high relative risks. These model maps describe  
83 new exposure hypotheses that warrant further epidemiological investigations on existing  
84 challenges and opportunities for disease surveillance and etiology

## 85 **Motivation of the study**

86 The HIV and TB diseases have a co-epidemic overlap in their epidemiologic characteristics and  
87 clinical manifestations [17]. Both the HIV and TB pathogens interact synergistically,  
88 accelerating the progress of illness thereby increasing the likelihood of death [18]. TB is a  
89 communicable disease and a major cause of ill health globally that affects the lungs (pulmonary)  
90 but can also affect other sites (extrapulmonary) [19,20]. Despite being a curable and preventable  
91 disease, TB is the leading cause of death from bacterial infection worldwide and undoubtedly  
92 representing a global public health priority [21–24]. TB is also the leading cause of morbidity  
93 and mortality among people living with HIV/AIDS [24], accounting for approximately 40% of  
94 deaths globally [20]. HIV disease is equally a major global health concern causing substantial  
95 morbidity, mortality rate, human suffering, and development challenges [25]. The rapid disease  
96 progression and associated leading opportunistic infection, TB, contribute to the high mortality  
97 rates [26]. Beyond affecting the health of individuals, HIV and TB diseases are stigmatized [17]  
98 and have a significant impact on the social, economic and political stability of the hardest-hit  
99 countries [27,28].

100 Kenya suffers from the dual epidemics ranking 4<sup>th</sup> and 15<sup>th</sup> globally in the high disease burden  
101 for HIV and TB respectively [29–31]. The high HIV prevalence in Kenya is the major driver of  
102 TB related mortality and TB prevalence is also the leading cause of HIV related mortality [31].  
103 Studies on TB and HIV incidences in Kenya have limited spatial and temporal scoping making  
104 generalizations of their findings to the whole country difficult. This study uses routine case  
105 notification data to provides more accurate estimates and insights on the elevated risk areas of  
106 HIV and TB individually and jointly over time. By using the spatiotemporal approach to  
107 modeling HIV and TB diseases simultaneously, we present the shared and disease-specific

108 spatial risk patterns and explore their temporal evolution. The joint model also determines the  
109 combined and disease-specific elevated risk areas.

## 110 **Materials and methods**

### 111 **Study location**

112 The study was conducted in Kenya, a country of great diversity situated in East Africa extending  
113 between latitudes  $4^{\circ}30'N$  and  $4^{\circ}30'S$  and longitudes  $34^{\circ}00'E$  and  $42^{\circ}00'E$  [32]. Kenya has a  
114 coastline stretch of approximately 14420 km along the Indian ocean mostly covered by salt-  
115 tolerant mangrove trees that creates a distinctive ecological zone [33]. The total coverage area of  
116 Kenya is  $583,367\text{km}^2$  with  $569,140\text{km}^2$  as land area and  $14,227\text{km}^2$  being water area [34]. The  
117 diversity of Kenya's landscape is shaped by four distinguishable relief zones; these are the  
118 coastal and eastern broad plains, the central and western highlands, the Rift Valley and Lake  
119 Victoria basins [35].

120 Kenya is administratively subdivided into 47 counties as the first level of administrative  
121 subdivisions which in turn are further subdivided into 290 sub-counties and 1450 wards as the  
122 second and third levels of administrative subdivisions respectively [36]. The population of  
123 Kenya is unevenly distributed throughout the country and predominantly urban. The population  
124 density has remained on the increase from 77.9% in 2012 to 88.2% in 2017 per sq.km [37–39].  
125 Supplementary information S2 presents the geospatial arrangements and the list of the 47  
126 counties of Kenya according to their corresponding geographic codes as used in this study. The  
127 population estimates per county from 2012 – 2017 are in supplementary information S3.

128 A big obstacle to human capital development in Kenya is health challenges. Many people are  
129 exposed to a wide range of disease burdens largely because of the country's geographical,  
130 economic, political and climatic conditions [40] which are further compounded by inadequate  
131 resources to mitigate the impact of health risks [41]. Presently, cases of emerging and re-  
132 emerging diseases – like TB and HIV - are on the rise thereby having important implications on  
133 public health policy processes [42]. Understanding variations in incidence trends at the county  
134 level – where health services are planned, organized and delivered – is essential in addressing  
135 health inequalities.

## 136 **Data Sources**

137 This study considered routine case notification data on TB and HIV diseases in 47 counties of  
138 Kenya for 6 years, 2012-2017. Case notifications are data from specific subpopulations who seek  
139 treatment and care from health facilities; these are geographically representative of nearby  
140 populations. The data were collected and made available by two main sources; the National  
141 Tuberculosis Leprosy & Lung Disease Program (NTLD-P) and National AIDS & STIs Control  
142 Program (NAS COP). The Government of Kenya has routine case-based monitoring and  
143 reporting regulations for TB and HIV diseases through the NLTP and NAS COP programs. The  
144 Integrated Electronic Medical Records (EMR) Data Warehouse (IDWH) is the on-line case-  
145 based repository hosted by NAS COP accommodating all EMR databases from all health  
146 facilities across the country. It operates both as a repository and analytics platform presenting  
147 data through interactive dashboards and ad-hoc data analysis. Health facilities update their EMR  
148 databases into the IDWH on a monthly basis. The Tuberculosis Information from Basic Unit  
149 (TIBU) is the centrally located case-based surveillance system hosted by NLTP that allows for  
150 real-time reporting. Since its inception in 2012, TIBU has made notifications of TB patients very

151 timely and instant in report generation. All public, faith-based and private treatment centers in  
152 the country enter data into the TIBU system. There are 301 TB control zones across the 47  
153 counties of Kenya which are coordinated by the Sub County TB and Leprosy Coordinators  
154 (SCTLCs), who are responsible for notifying TB cases from health facilities in their control  
155 zones into the TIBU system. Both programs have adapted the data recording and reporting  
156 standards of WHO at the health facilities in every county and the national surveillance system.  
157 For the purpose of this study, we analyze the data aggregated per county per year for the period  
158 2012-2017.

## 159 **Ethical considerations**

160 This study involved the use of non-identifiable secondary data collected as part of the routine  
161 programs monitoring. Ethical permission to use the routinely collected data was obtained from  
162 NASCOP and NLTP, which are commissioned by the Ministry of Health to host the data  
163 surveillance systems for the HIV and TB programmes respectively. The study was subjected to  
164 Human Research Protection Review by the African Medical Research Foundation (AMREF  
165 Health Africa) Ethical and Scientific Review Committee (ESRC), which determined it not to  
166 constitute human participation.

## 167 **Hierarchical Model specification**

168 We formulated a statistical model that combined the spatiotemporal methods to the modeling of  
169 HIV and TB simultaneously. The study applied a full Bayesian Hierarchical approach on the  
170 model to estimate the spatial and temporal parameters for the two diseases individually and  
171 jointly. We applied the spatial and temporal specifications of [9] and [43] to our model. While  
172 [9] mapped a single disease for two subpopulations, we mapped two diseases -HIV and TB- with

173 co-epidemic overlap. They were also keen to interpret the unexpected differential risks between  
174 two subpopulations; our aim was to determine the shared and specific spatiotemporal patterns to  
175 interpret the relationships between the two diseases. Unlike [43], our model accounts for the joint  
176 space-time interaction using similar specifications as [9].

### 177 **a. Log-linear model**

178 The initial step in defining our model within the Hierarchical Bayesian framework was selecting  
179 the probability distribution for the observed data. This study utilized the Poisson distribution  
180 from the exponential family. For county  $s$  in the year  $t$ , we modeled cases notification  $y_{dst}$  for  
181 disease  $d$ , where  $d=1$  is HIV and  $d=2$  is TB as;

$$182 \quad y_{dst} \sim \text{Poisson}(\mu_{dst}), \quad \mu_{dst} = \rho_{dst} E_{dst}.$$

183 This study defined the mean  $\mu_{dst}$  in terms of the unknown relative risk  $\rho_{dst}$  and the expected  
184 number of cases  $E_{dst}$ . We computed  $E_{dst}$  per county per year. Our statistical consideration for the  
185 standard population  $N$  was the average of the pooled county population estimates, i.e.  $N = \frac{P}{T}$ ,  
186 where  $P$  is the estimated population of county  $s$ , which we are considering to be the population at  
187 risk of disease  $d$  and  $T$  is the number of years, which is six years for this study. We calculated the  
188 crude rate as  $R_{dst} = \frac{\sum y_{dst}}{P_{dst}}$ , where  $\sum y_{dst}$  and  $P_{dst}$  are the number of cases for disease  $d$  and  
189 estimated population respectively for county  $s$  in the year  $t$ . We then multiplied the crude rate by  
190 the standard population to obtain the expected number of cases for disease  $d$  for county  $s$  in the  
191 year  $t$  as;

$$E_{dst} = R_{dst} \times N$$

192 The linear predictor of the unknown relative risk was on the logarithmic scale,  $\eta_{dst} = \log(\rho_{dst})$   
 193 which is the recommended invertible link function for the Poisson family of distributions. The  
 194 variability of the cases around the unknown relative risks  $\rho_{dst}$  for HIV and TB respectively were  
 195 as follows;

$$196 \quad y_{1st} \sim \text{Pois}(\rho_{1st} E_{1st}) \quad \eta_{1st} = \alpha_1 + \lambda_s \delta + \xi_t \kappa + \beta_{1s} + \gamma_{1t} + v_{st}$$

$$197 \quad y_{2st} \sim \text{Pois}(\rho_{2st} E_{2st}) \quad \eta_{2st} = \alpha_2 + \frac{\lambda_s}{\delta} + \frac{\xi_t}{\kappa} + \beta_{2s} + \gamma_{2t} + v_{st}$$

198 The linear predictor was defined by the following terms; the shared spatial effect, ( $\lambda$   
 199  $= \{\lambda_s\}_{s=1,2,\dots,S}$ ), the disease-specific spatial effect ( $\beta = \{\beta_{ds}\}_{d=1,2; s=1,2,\dots,S}$ ), the shared time trend ( $\xi$   
 200  $= \{\xi_t\}_{t=1,\dots,T}$ ), the disease-specific time trend ( $\gamma = \{\gamma_{dt}\}_{d=1,2; t=1,\dots,T}$ ), and the space-time interaction  
 201 term ( $\mathbf{v} = \{v_{st}\}_{s=1,\dots,S; t=1,\dots,T}$ ). The notations  $\alpha_d$ ,  $\lambda_s$ , and  $\xi_t$  captured disease-specific intercept, space  
 202 and time main effects respectively whereas  $\gamma_{dt}$  and  $\beta_{ds}$  were disease-time and disease-space  
 203 interactions of order 2 respectively. The coefficients  $\delta$  and  $\kappa$  represented the spatial and temporal  
 204 scaling parameters on the shared term to the risk of TB compared to HIV. Even though the  
 205 overall relative risk level is the same for both diseases, the magnitude of the area-specific and  
 206 time-specific relative risks may differ - hence the need for the scaling parameters [9,44,45].  
 207 Therefore, contribution of the shared component to the overall relative risk is weighted by the  
 208 scaling parameters to allow different risk gradients for each disease.

209 We applied a symmetric formulation to both the shared and disease-specific random effects,  
 210 implying that  $\lambda_s$ , and  $\xi_t$  captured the common spatial and temporal patterns. The terms  $\gamma_{dt}$  and  $\beta_{ds}$   
 211 allowed for departures from the shared patterns for the different diseases. The space-time  
 212 interaction term,  $v_{st}$  provided additional flexibility towards identifying varying patterns. We

213 assumed the shared random effects to be the structured effects and the disease-specific random  
214 effects to be unstructured effects

## 215 **b. Bayesian prior specification**

216 In a Bayesian framework, random effects are unknown quantities assigned to prior distributions  
217 that reflect any prior knowledge on the structure of the effects. The model assigned priors and  
218 generated the posterior distribution used for deriving the conditional densities for posterior  
219 sampling.

220 The spatial random effects  $\lambda_s$  and  $\beta_s$  assumed a spatially correlated prior distribution (CAR  
221 spatial priors) with a neighborhood matrix  $W$  defined by contiguity;  $\tau_\lambda$  and  $\tau_\beta$  were the prior  
222 hyperparameters. The CAR spatial prior defines a binary specification for the geographical  
223 contiguity such that correlation is certain for geographically adjacent areas that is:

$$S_{kj} = \begin{cases} 1 & \text{if } k \sim j \\ 0 & \text{otherwise} \end{cases}$$

224 The non-contiguous areal units are conditionally independent given the values of the remaining  
225 random effects. To reflect the prior of yearly fluctuations for  $\xi_t$  and  $\gamma_{dt}$ , the study assumed a  
226 random walk prior of order 1 (RW (1)) with a weighted matrix  $Q$  which defines the temporal  
227 neighborhood with  $\tau_\xi$  and  $\tau_\gamma$  as the prior hyperparameters. The space-time interaction term  $v_{st}$   
228 prior was a simple exchangeable hierarchical structure  $v_{st} \sim N(0, \tau_v)$ . We defined improper priors  
229 for the intercept as  $\alpha \sim N(0,0)$ . The scaling parameters assume normal priors  $N(0, \sigma^2)$  which are  
230 symmetric around zero, therefore, any value is as equally likely as the reciprocal value and the  
231 posterior distribution of the relative risks for each disease are exactly the same. For the  
232 distribution of the hyper-parameters, we assumed the default specifications of INLA whereby we

233 assigned minimally informative priors on the log of the precision of both the structured and  
234 unstructured effects,  $\log\text{Gamma}(1, 0.0005)$ . INLA estimates the posterior marginal distribution  
235 for the hyperparameters using an integration-free algorithm described in [46]. We use INLA  
236 approach for the model estimations as it is capable of handling complex models with large  
237 predictor spaces. Equally the approach does not require convergence checking (unlike McMC)  
238 [47,48] as it does not suffer from slow convergence and poor mixing.

## 239 Results

240 To determine the areas of high risks, we created the spatial maps of the standardized incidence  
241 ratio for HIV (Fig 1) and TB (Fig 2). The two diseases displayed varying spatiotemporal  
242 patterns, though most of the regions of high risk for HIV were also high risk for TB. The  
243 progression of the risk during the period 2012 – 2017 was much faster in TB as compared to HIV

244 **Fig 1. Standardized incidence ratio  $\left(\frac{O_{dst}}{E_{dst}}\right)$  for HIV**

245 **Fig 2. Standardized incidence ratio  $\left(\frac{O_{dst}}{E_{dst}}\right)$  for TB**

246 We considered the analysis of the combined spatial patterns in the model. Table 1 provides the  
247 summary statistics of the shared and disease-specific spatial effects while Fig 3 presents the  
248 relative risk of the combined spatial patterns for HIV and TB. The estimates of the different  
249 spatial effects are statistically significant at 5% as depicted by the credible intervals. Both HIV  
250 and TB had similar areas of high risk in the South West, Central and South regions of Kenya.  
251 Further, TB revealed additional areas of high risk in the North West and North of Kenya.

252 **Table 1. Summary statistics of the shared and disease-specific spatial and temporal effects**

Parameters	mean	2.5%	97.5%
<b>Fixed effects:</b>			
$\alpha_1$	0.660	0.622	0.700
$\alpha_2$	0.885	0.872	0.899

---

**Random effects:**

$\tau_{\beta_{1s}}$	2.301	1.566	4.191
$\tau_{\beta_{2s}}$	24.557	4.389	588.749
$\tau_{\lambda_s}$	1.319	1.121	1.738
$\tau_{\gamma_{1t}}$	3.222	2.611	139.491
$\tau_{\gamma_{2t}}$	53.038	2.464	831.308
$\tau_{\xi_t}$	1.030	1.003	1.138
$\tau_{\nu_{st}}$	3.219	2.561	4.568

---

253

254

**Fig 3. Relative risk of the combined spatial patterns ( $\lambda_s + \beta_{ds}$ )**

255 The posterior means of the shared and disease-specific spatial patterns are presented in Fig 4. In

256 all the maps, common areas of high risk were in the west part of the country. Equally, the shared

257 spatial pattern showed fewer regions of high risk compared to TB-specific spatial patterns. This

258 could be because of higher dependence of HIV on the shared spatial term making the shared

259 pattern to account for most of HIV spatial patterns

260

**Fig 4. Relative risk of shared spatial patterns ( $\lambda_s$ ) and disease specific spatial patterns ( $\beta_{ds}$ )**

261 The posterior means of the shared, disease-specific, and combined temporal trends are in Fig 5.

262 The shared temporal effect displayed the overall decreasing risk trend in time with estimates

263 close to zero for most years. The HIV temporal trend exhibited increasing risk over time

264 displaying relative risks between 0.8 - 1.2 whereas the TB temporal trend presented a nearly

265 constant trend across the years with relative risks close to one. The combined temporal trends for

266 HIV and TB showed an increasing risk trend for both diseases. From the combined temporal

267 trends graph, HIV risk was relatively lower than TB in 2012 and 2013. From 2015 - 2017, the

268 HIV risk trend surpassed that of TB. Even though the shared effect shows minimal evidence on

269 the joint diseases, the disease-specific and combined temporal effects show very similar temporal

270 pattern.

271

**Fig 5. Relative risk of the shared  $\xi_t$ , specific  $\gamma_{dt}$  and the combined temporal trends ( $\xi_t + \gamma_{dt}$ )**

272 The posterior probabilities for the smoothed joint Spatio-temporal interaction  $P(e^{(v_{st})} > 1|y)$   
273 are in Fig 6, and the posterior estimates are presented in Table 1. Over the years the joint  
274 incidence risk reduced progressively with all spatial regions having a relative risk less than 1.

275 **Fig 6. Posterior probabilities for the joint Spatio-temporal interaction  $P(e^{(v_{st})} > 1|y)$**   
276 Fig 7(a) displays the spatial pattern of the posterior mean for the joint disease risk  $\zeta_s = e^{(\lambda_s + \beta_{ds})}$ .  
277 The uncertainty associated with the posterior means, which lays in the exceedance risk  $\zeta_s: P$   
278  $(\zeta_s > 1|y)$ , is presented in Fig 7(b). The extreme West and Central regions depicted elevated joint  
279 relative risks characterized by a spatial relative risk above one and exceedance probability above  
280 0.8

281 **Fig 7. Maps of the spatial pattern of joint disease risk ( $\zeta_s = e^{(\lambda_s + \beta_{ds})}$ ) and uncertainty for the spatial effect ( $\zeta_s: P(\zeta_s >$   
282  $1|y)$ )**

## 283 Discussion

284 We presented a Bayesian Hierarchical approach to the joint modeling of spatio-temporal  
285 routinely collected health data. The joint modeling approaches have yielded substantial co-  
286 dynamic insights via mathematical, statistical and computational approaches [49]. By optimizing  
287 the spatial scale at different points in time, spatial heterogeneity influences the interpretation of  
288 temporal patterns more especially in disease dynamics and surveillance [49]. This is especially  
289 true for the case of HIV and TB that have significant geographic overlap and are subject to  
290 diverse regional variations in their co-dynamics. HIV and TB rank as the leading causes of death  
291 from infectious diseases globally with an estimated 2.5 million new HIV infections and 8.7  
292 million incidences of TB annually [50,51]. They have a close link even though their biological  
293 co-existence and co-dynamics vary regionally with much burden in Sub-Saharan Africa [31,52].  
294 This study determined the space-time joint risk trends of HIV and TB in Kenya. Our model

295 enabled us to define the shared and specific spatial and temporal patterns of HIV and TB thus  
296 identifying similarities and differences in the distribution of the relative risks associated with  
297 each disease. The model separately estimated the shared and disease-specific relative risks and  
298 displayed the spatial-disease, temporal-disease, and spatio-temporal disease interaction effects  
299 across all regions. We included scaling components on the shared spatial and temporal  
300 parameters to compare their strength signals for HIV and TB.

301 The disease-specific spatial and temporal patterns detected areas with varying spatial trends and  
302 temporal variations for each disease. The HIV high-risk areas were to the further west of Kenya  
303 spreading towards the central and further south. The TB high-risk areas were similar to the HIV  
304 high-risk areas but also spread upwards towards the North. The TB geographical progression in  
305 relation to HIV was proportionally higher which could reflect environmental factors favoring the  
306 TB spread in the high-density settlements especially in the towards the North. These findings are  
307 corroborated in other studies by [31,53]. Looking beyond Kenya, studies by [54] revealed that  
308 TB appeared to outpace HIV in Rwanda and Burundi while HIV greatly outpaced TB in  
309 Mauritania, Senegal and The Gambia

310 Joint temporal analysis is important when investigating the temporal coherency of  
311 epidemiological trends from the same area [54]. In our study, the shared temporal trend  
312 presented a steep decrease from 2012 to 2013 then an almost constant risk without any  
313 significant variation over time. However, the disease-specific and combined temporal trends  
314 presented an increased risk over time. The temporal trend of HIV risk was lower than that of TB  
315 for the years 2012 and 2013 but between 2015 and 2017 the HIV risk was higher than TB risk.  
316 Similar studies in Sub-Saharan Africa that utilized routinely collected data observed similar  
317 temporal dynamics [55–58]. A possible explanation could be HIV drives TB related incidences,

318 therefore, the incidence and prevalence of TB increases (decreases) with increasing (decreasing)  
319 HIV trends [59–61].

320 Our study successfully detected the spatial congruence in the distribution of TB and HIV in  
321 approximately 29 counties around the western, central and southern regions of Kenya. The  
322 spatial patterns were largely similar for Homabay, Siaya, Kisumu, Busia and Migori counties as  
323 the high risk with Mandera, Wajir and Garissa counties at low risk for both HIV and TB. The  
324 distribution of the shared relative risks had minimal difference with the HIV disease-specific  
325 relative risk whereas that of TB presented many more counties as high-risk areas. This could be  
326 attributed to higher dependence of HIV on the shared spatial term making the shared pattern  
327 account for most HIV spatial patterns. Similar studies by [62] in China and [53] in Uganda  
328 observed significantly persistent clusters for TB and HIV using the spatial co-clustering  
329 approach. They examined the clusters exhibited by each disease as well as the combined.

330 Our model also presented areas of elevated joint risk by looking at the posterior probabilities of  
331 the relative risk to detect the joint geographical patterns. There was strong evidence of disease-  
332 time, disease-space and space-time interactions. Studies by [62] and [63] also found a strong  
333 association on the joint risks of HIV and TB they used bivariate maps to show that the joint  
334 distribution for both TB and HIV diseases was spatially heterogeneous across Brazil.

335 The primary limitation of the study is using routine case notification data as a surrogate measure  
336 of the general population of infected persons; this type of data has challenges of underreporting.  
337 The spatial regions were based on the counties since there was no data for sub-county or health  
338 facility levels. The age and sex standardized rates were not utilized as the HIV data was not  
339 disaggregated by age and gender. Whereas this kind of data is not completely spatially random

340 for the joint epidemic burden, it still captures the spatiotemporal patterns of incidence risk, which  
341 is the ultimate goal of this study.

## 342 **Conclusions**

343 We defined a joint Bayesian space-time model of two related diseases to jointly quantify the risk  
344 of TB relative to HIV thereby facilitating the comparative benefits obtained across populations.  
345 The disease burden was apparent at each spatial level of analysis. Identifying the spatial and  
346 temporal similarities between HIV and TB enabled us to understand the shared risk. The  
347 flexibility and informative outputs of Bayesian Hierarchical Models played a key role in  
348 clustering these risk areas. Quantifying how HIV and TB varied together provided additional  
349 insights towards collaborative monitoring of the diseases and control efforts. To control the HIV-  
350 TB twin epidemic it is important to determine the TB life history that could greatly reduce TB  
351 incidences if intervened and which stages of HIV needs optimized TB control benefits

## 352 **Acknowledgments**

353 The authors sincerely acknowledge the National Tuberculosis, Leprosy and Lung Cancer  
354 Program (NLTP) and the National AIDS and STI Control Program (NAS COP) for their cordial  
355 support in providing the data used in this study

## 356 **References**

- 357 1. Riebler A, Sørbye SH, Simpson D, Rue H. An intuitive Bayesian spatial model for disease  
358 mapping that accounts for scaling. *Stat Methods Med Res.* 2016;25(4):1145–65.
- 359 2. Schrödle B, Held L. *A Primer on Disease Mapping and Ecological Regression Using*

- 360 INLA. *Comput Stat.* 2010;26(2):241–58.
- 361 3. Ugarte M, Adin A, Goicoa T, Militino A. On fitting spatio-temporal disease mapping  
362 models using approximate Bayesian inference. *Stat Methods Med Res.* 2014;23(6):507–  
363 30.
- 364 4. Dabney AR, Wakefield JC. Issues in the mapping of two diseases. *Stat Methods Med Res.*  
365 2005;14(1):83–112.
- 366 5. Baker J, White N, Mengersen K, Rolfe M, Morgan GG. Joint modelling of potentially  
367 avoidable hospitalisation for five diseases accounting for spatiotemporal effects: A case  
368 study in New South Wales, Australia. *PLoS One.* 2017;12(8):e0183653.
- 369 6. Rotejanaprasert C, Lawson AB, Iamsirithaworn S. Spatiotemporal multi-disease  
370 transmission dynamic measure for emerging diseases: an application to dengue and zika  
371 integrated surveillance in Thailand. *BMC Med Res Methodol.* 2019;19(1):200.
- 372 7. Earnest A, Beard JR, Morgan G, Lincoln D, Summerhayes R, Donoghue D, et al. Small  
373 area estimation of sparse disease counts using shared component models-application to  
374 birth defect registry data in New South Wales, Australia. *Heal Place.* 2010;16(4):684–93.
- 375 8. Tzala E. *Multivariate analysis of spatial and temporal variation in cancer mortality.*  
376 Imperial College London; 2004.
- 377 9. Richardson S, Abellan JJ, Best N. Bayesian spatio-temporal analysis of joint patterns of  
378 male and female lung cancer risks in Yorkshire (UK). *Stat Methods Med Res.*  
379 2006;15(4):385–407.
- 380 10. Oleson JJ, Smith BJ, Kim H. *Joint Spatio-Temporal Modeling of Low Incidence Cancers*

- 381            Sharing Common Risk Factors. *J Data Sci.* 2008;6:105–23.
- 382    11.    Tzala E, Best N. Bayesian latent variable modelling of multivariate spatio-temporal  
383            variation in cancer mortality. *Stat Methods Med Res.* 2008;17(1):97–118.
- 384    12.    Baker JF. *Bayesian Spatiotemporal Modelling of Chronic Disease Outcomes.* Queensland  
385            University of Technology; 2017.
- 386    13.    Meliker JR, Sloan CD. *Spatio-temporal epidemiology: Principles and opportunities.* *Spat*  
387            *Spatiotemporal Epidemiol.* 2011;2(1):1–9.
- 388    14.    Lee D. A comparison of conditional autoregressive models used in Bayesian disease  
389            mapping. *Spat Spatiotemporal Epidemiol.* 2011;2:79–89.
- 390    15.    Bivand RS, Pebesma E, Gomes-Rubio V. *Applied Spatial Data Analysis with R.* 2nd ed.  
391            Gentleman R, Hornik K, Parmigiani GG, editors. Springer; 2013.
- 392    16.    Musenge E. *Modeling spatiotemporal patterns of childhood HIV/TB related mortality and*  
393            *malnutrition: Applications to agincourt data in rural South Africa.* University of the  
394            Witwatersrand. University of the Witwatersrand; 2013.
- 395    17.    Tsiouris SJ, Gandhi NR, El-Sadr WM, Gerald F. Tuberculosis and HIV-Needed: A New  
396            Paradigm for the Control and Management of Linked Epidemics. *J Int AIDS Soc.*  
397            2007;9(3):62.
- 398    18.    Mayer KH, Hamilton CD. Synergistic Pandemics: Confronting the Global HIV and  
399            Tuberculosis Epidemics. *Clin Infect Dis.* 2010;50(s3):S67–70.
- 400    19.    WHO. *Global tuberculosis report 2018.* Geneva (Switzerland); 2018.
- 401    20.    Macneil A, Glaziou P, Sismanidis C, Maloney S, Floyd K. *Global epidemiology of*

- 402 tuberculosis and progress toward achieving global targets — 2017. *Morb Mortal Wkly*  
403 *Rep.* 2019;68(11):263–6.
- 404 21. Garcia-saenz A, Saez M, Napp S, Casal J, Luis J, Acevedo P, et al. Spatio-temporal  
405 variability of bovine tuberculosis eradication in Spain (2006–2011). *Spat Spatiotemporal*  
406 *Epidemiol.* 2014;10:1–10.
- 407 22. Jacobs AJ, Mongkolsapaya J, Screaton GR, McShane H, Wilkinson RJ. Antibodies and  
408 tuberculosis. *Tuberculosis.* 2016;101:102–13.
- 409 23. Saunders MJ, Tovar MA, Datta S, Evans BEW, Wingfield T, Evans CA. Pragmatic  
410 tuberculosis prevention policies for primary care in low- and middle-income countries.  
411 *Eur Respir J.* 2018;51(3):1800315.
- 412 24. UNAIDS. Joint United Nations Programme on HIV/AIDS. Global report: UNAIDS report  
413 on the global AIDS epidemic 2010. 2010.
- 414 25. Mgori NK, Mash R. HIV and/or AIDS-related deaths and modifiable risk factors: A  
415 descriptive study of medical admissions at Oshakati Intermediate Hospital in Northern  
416 Namibia. *African J Prim Heal Care Fam Med.* 2015;7(1):e1–7.
- 417 26. Burrage A, Patel M, Mirkovic K, Dziuban E, Teferi W, Broyles L, et al. Trends in  
418 Antiretroviral Therapy Eligibility and Coverage Among Children Aged <15 Years with  
419 HIV Infection - 20 PEPFAR-Supported Sub-Saharan African Countries, 2012-2016.  
420 *MMWR Morb Mortal Wkly Rep.* 2018;67(19):552–5.
- 421 27. HIV.gov. Global Statistics [Internet]. 2018. Available from: [https://www.hiv.gov/hiv-](https://www.hiv.gov/hiv-basics/overview/data-and-trends/global-statistics)  
422 [basics/overview/data-and-trends/global-statistics](https://www.hiv.gov/hiv-basics/overview/data-and-trends/global-statistics)

- 423 28. KFF. Global HIV/AIDS Epidemic [Internet]. 2018. Available from:  
424 <https://www.kff.org/global-health-policy/fact-sheet/the-global-hiv-aids-epidemic/>
- 425 29. Otiende V, Achia T, Mwambi H. Bayesian modeling of spatiotemporal patterns of TB-  
426 HIV co-infection risk in Kenya. *BMC Infect Dis.* 2019;19:902.
- 427 30. Enos M, Sitienei J, Ong'ang'o J, Mungai B, Kamene M, Wambugu J, et al. Kenya  
428 tuberculosis prevalence survey 2016: Challenges and opportunities of ending TB in  
429 Kenya. Hozbor DF, editor. *PLoS One.* 2018;13(12):e0209098.
- 430 31. Onyango DO, Yuen CM, Cain KP, Ngari F, Masini EO, Borgdorff MW. Reduction of  
431 HIV-associated excess mortality by antiretroviral treatment among tuberculosis patients in  
432 Kenya. Cameron DW, editor. *PLoS One.* 2017;12(11):e0188235.
- 433 32. Google Earth. Map showing location of Kenya [Internet]. Available from:  
434 <https://www.google.com/earth/>
- 435 33. Yap W, Landoy R, Fisheries Department FAO. Report on a Survey of the Coastal Areas  
436 of Kenya for Shrimp Farm Development [Internet]. 1986. Available from:  
437 <http://www.fao.org/3/AC574E00.htm>
- 438 34. United Nations Office Nairobi. Introductory guide to Kenya [Internet]. Division of  
439 Conference Services. Available from: <https://dcs.unon.org/node/75>
- 440 35. Mathu EM, Davies TC. Geology and the environment in Kenya. *J African Earth Sci.*  
441 1996;23(4):511–39.
- 442 36. CoG-KE. The 47 Counties of Kenya [Internet]. Available from: [http://cog.go.ke/the-47-](http://cog.go.ke/the-47-counties)  
443 counties

- 444 37. Knoema. Kenya Population density, 1960-2018 [Internet]. Available from:  
445 <https://knoema.com/atlas/Kenya/Population-density>
- 446 38. GoK, UNFPA - Kenya Country Office. Kenya Population Situation Analysis. 2013.
- 447 39. The World Bank. World Development Indicators (WDI) Data Catalog [Internet].  
448 Available from: <https://datacatalog.worldbank.org/dataset/world-development-indicators>
- 449 40. Ministry of medical services, Ministry of public health & sanitation. The Kenya health  
450 sector strategic & investment plan July 2012 - June 2017 [Internet]. 2017. Available from:  
451 [http://www.health.go.ke/wp-content/uploads/2016/03/MINISTERIAL-STRATEGIC-](http://www.health.go.ke/wp-content/uploads/2016/03/MINISTERIAL-STRATEGIC-INVESTMENT-PLAN.pdf)  
452 [INVESTMENT-PLAN.pdf](http://www.health.go.ke/wp-content/uploads/2016/03/MINISTERIAL-STRATEGIC-INVESTMENT-PLAN.pdf)
- 453 41. Institute for Health Metrics and Evaluation. Kenya Profile. Seattle, WA: IHME,  
454 University of Washington [Internet]. 2018. Available from:  
455 <http://www.healthdata.org/Kenya>
- 456 42. Achoki T, Miller-Petrie MK, Glenn SD, Kalra N, Lesego A, Gathecha GK, et al. Health  
457 disparities across the counties of Kenya and implications for policy makers, 1990–2016: a  
458 systematic analysis for the Global Burden of Disease Study 2016. *Lancet Glob Heal.*  
459 2019;7(1):e81–95.
- 460 43. Gómez-Rubio V, Palmí-Perales F, López-Abente G, Ramis-Prieto R, Fernández-Navarro  
461 P. Bayesian joint spatio-temporal analysis of multiple diseases. *Stat Oper Res Trans.*  
462 2019;43(1):51–74.
- 463 44. Knorr-Held L, Best NG. A shared component model for detecting joint and selective  
464 clustering of two diseases. *J R Stat Soc Ser A (Statistics Soc.* 2001;164(1):73–85.

- 465 45. Held L, Natár'io I, Fenton SE, Rue H, Becker N. Towards joint disease mapping. *Stat*  
466 *Methods Med Res.* 2005;14:61–82.
- 467 46. Martins TG, Simpson D, Lindgren F, Rue H. Bayesian computing with INLA: New  
468 features. *Comput Stat Data Anal.* 2013;67:68–83.
- 469 47. Günhan BK, Friede T, Held L. A design-by-treatment interaction model for network meta-  
470 analysis and meta-regression with integrated nested Laplace approximations. *Res Synth*  
471 *Methods.* 2018;9(2):179–94.
- 472 48. Gómez-Rubio V, Palmí-Perales F. Multivariate posterior inference for spatial models with  
473 the integrated nested Laplace approximation. *J R Stat Soc Ser C (Applied Stat.*  
474 *2019;68(1):199–215.*
- 475 49. Sánchez MS, Lloyd-Smith JO, Williams BG, Porco TC, Ryan SJ, Borgdorff MW, et al.  
476 Incongruent HIV and tuberculosis co-dynamics in Kenya: interacting epidemics monitor  
477 each other. *Epidemics.* 2009;1(1):14–20.
- 478 50. WHO. A guide to monitoring and evaluation for collaborative TB/HIV activities. 2015.
- 479 51. Venturini E, Turkova A, Chiappini E, Galli L, de Martino M, Thorne C. Tuberculosis and  
480 HIV co-infection in children. *BMC Infect Dis.* 2014;14(Suppl 1):S5.
- 481 52. Gwitira I, Murwira A, Mberikunashe J, Masocha M. Spatial overlaps in the distribution of  
482 HIV/AIDS and malaria in Zimbabwe. *BMC Infect Dis.* 2018;18:598–607.
- 483 53. Aturinde A, Farnaghi M, Pilesjö P, Mansourian A. Spatial analysis of HIV-TB co-  
484 clustering in Uganda. *BMC Infect Dis.* 2019;19(1):612.
- 485 54. Sánchez MS, Lloyd-Smith JO, Getz WM. Monitoring linked epidemics: the case of

- 486 tuberculosis and HIV. *PLoS One*. 2010;5(1):e8796.
- 487 55. Assebe LF, Reda HL, Wubeneh AD, Lerebo WT, Lambert SM. The effect of isoniazid  
488 preventive therapy on incidence of tuberculosis among HIV-infected clients under pre-  
489 ART care, Jimma, Ethiopia: a retrospective cohort study. *BMC Public Health*.  
490 2015;15:346–54.
- 491 56. Nakiyingi L, Ssengooba W, Nakanjako D, Armstrong D, Holshouser M, Kirenga BJ, et al.  
492 Predictors and outcomes of mycobacteremia among HIV-infected smear- negative  
493 presumptive tuberculosis patients in Uganda. *BMC Infect Dis*. 2015;15:62–9.
- 494 57. Sabasaba A, Mwambi H, Somi G, Ramadhani A, Mahande MJ. Effect of isoniazid  
495 preventive therapy on tuberculosis incidence and associated risk factors among HIV  
496 infected adults in Tanzania: a retrospective cohort study. *BMC Infect Dis*. 2019;19(1):62.
- 497 58. Yirdaw KD, Jerene D, Gashu Z, Edginton ME, Kumar AM V, Letamo Y, et al. Beneficial  
498 effect of isoniazid preventive therapy and antiretroviral therapy on the incidence of  
499 tuberculosis in people living with HIV in Ethiopia. *PLoS One*. 2014;9(8):e104557.
- 500 59. Geldmacher C, Zumla A, Hoelscher M. Interaction between HIV and Mycobacterium  
501 tuberculosis: HIV-1-induced CD4 T-cell depletion and the development of active  
502 tuberculosis. *Curr Opin HIV AIDS*. 2012;7(3):268–75.
- 503 60. Naing C, Mak JW, Maung M, Wong SF, Kassim AIBM. Meta-analysis: the association  
504 between HIV infection and extrapulmonary tuberculosis. *Lung*. 2013;191(1):27–34.
- 505 61. Pontillo A, Carvalho MS, Kamada AJ, Moura R, Schindler HC, Duarte AJS, et al.  
506 Susceptibility to Mycobacterium tuberculosis infection in HIV-positive patients is

507 associated with CARD8 genetic variant. *J Acquir Immune Defic Syndr.* 2013;63(2):147–  
508 51.

509 62. Wei W, Wei-Sheng Z, Ahan A, Ci Y, Wei-Wen Z, Ming-Qin C. The Characteristics of TB  
510 Epidemic and TB/HIV Co-Infection Epidemic: A 2007-2013 Retrospective Study in  
511 Urumqi, Xinjiang Province, China. *PLoS One.* 2016;11(10):e0164947.

512 63. Ross JM, Henry NJ, Dwyer-Lindgren LA, de Paula Lobo A, Marinho de Souza F, Biehl  
513 MH, et al. Progress toward eliminating TB and HIV deaths in Brazil, 2001-2015: a spatial  
514 assessment. *BMC Med.* 2018;16:144–53.


## 515 **Supporting Information**

516 S1 Text. R codes used in the analysis


517 S2 Text. List of counties in Kenya

518 S3 Text. County population estimates 2012-2017


**2012**




**2013**




**2014**




**2015**




**2016**




**2017**




**2012**




**2013**




**2014**




**2015**




**2016**




**2017**




**HIV Combined spatial patterns**




**TB combined spatial patterns**




**SHARED**




**HIV**




**TB**




**Shared temporal trend**




**HIV temporal trend**




**TB temporal trend**




**Combined temporal trend**




**2012**




**2013**




**2014**



**2015**



**2016**



**2017**

